Vitamin intervention for stroke prevention trial: An efficacy analysis

Stroke

Volumn 36, Issue 11, 2005, Pages 2404-2409

  Spence, J David ^a,e   Bang, Heejung ^b,d   Chambless, Lloyd E ^b   Stampfer, Meir J ^c  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b IL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e Stroke Prevention and Atherosclerosis Research Centre   (Canada)

Author keywords

Homocysteine; Stroke; Stroke prevention; Vitamins

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; VITAMIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DATA ANALYSIS; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KAPLAN MEIER METHOD; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALABSORPTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SMOKING; STROKE; SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

AGED; CEREBROVASCULAR ACCIDENT; DISEASE-FREE SURVIVAL; FEMALE; FOLIC ACID; GLOMERULAR FILTRATION RATE; HOMOCYSTEINE; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; TREATMENT OUTCOME; VITAMIN B 12; VITAMINS;

EID: 27644521579     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000185929.38534.f3     Document Type: Article

References (35)

1. Graham IM, Daly L, Refsum H, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garçon D, Andria G, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. J Am Med Assoc. 1997;277:1775-1781.
2. Nygård O, Nordehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-236.
3. Nishinaga M, Shimada K. Heparan sulfate proteoglycan of endothelial cells: homocysteine suppresses anticoagulant active heparan sulfate in cultured endothelial cells. Rinsho Byori. 1994;42:340-345.
4. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest. 1993;92:1381-1386.
5. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-762.
6. Simioni P. The molecular genetics of familial venous thrombosis. Baillieres Best Pract Res Clin Haematol. 1999;12:479-503.
7. Stamler JS, Slivka A. Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev. 1996;54:1-30.
8. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation. 1999;99:1156-1160.
9. Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet. 1998;351:36-37.
10. Van den Berg M, Boers GH, Franken DG, Blom HJ, van Kamp GJ, Jakobs C, Rauwerda JA, Kluft C, Stehouwert CD. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest. 1995;25:176-181.
11. 6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. J Vasc Surg. 1994;20:933-940.
12. Leerink CB, van Ham AD, Heeres A, Duif PF, Bouma BN, van Rijn HJ. Sulfhydryl compounds influence immunoreactivity, structure and functional aspects of lipoprotein(a). Thromb Res. 1994;74:219-232.
13. Brattström LE. Vitamins as homocysteine-lowering agents. J Nutr. 1996; 126:S1276-S1280.
14. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering plasma total homocysteine to prevent recurrent stroke, myocardial infarction, and death in ischemic stroke patients: results of the Vitamin Intervention for Stroke Prevention (VISP) Randomized Trial. J Am Med Assoc. 2004;291: 565-575.
15. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340:1449-1454.
16. Rajan S, Wallace JI, Brodkin KI, Beresford SA, Allen RH, Stabler SP. Response of elevated methylmalonic acid to three dose levels of oral cobalamin in older adults. J Am Geriatr Soc. 2002;50:1789-1795.
17. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, Meier B, Turi ZG, Hess OM. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001;345:1593-1600.
18. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B(12), and-vitamin B(6) on clinical outcome after percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial. J Am Med Assoc. 2002;288:973-979.
19. Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kallmayer K, Pasalary MN, Scherer E, Dambrink JH. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004;350:2673-2681.
20. Spence JD, Cordy P, Kortas C, Freeman D. Spence JD, Cordy P, Kortas C, Freeman D. Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: no difference between 1 and 5 mg daily. Am J Nephrol. 1999;19:405-410.
21. 12 for total homocysteine and carotid plaque in the era of folate fortification of cereal grain products. CMAJ. 2005;172:1569-1573.
22. Spence JD, Howard VJ, Chambless LE, Malinow MR, Pettigrew LC, Stampfer M, Toole JF. Vitamin Intervention for Stroke Prevention (VISP) trial: rationale and design. Neuroepidemiology. 2001;20:16-25.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
24. Cox DR. Regression models and life-tables (with discussion). J Royal Stat Soc B. 1972;34:187-220.
25. Rader JI. Folic acid fortification, folate status and plasma homocysteine. J Nutr. 2002;132(suppl 8):2466S-2470S.
26. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction. J Am Med Assoc. 1992;268:877-881.
27. van Oort FV, Melse-Boonstra A, Brouwer IA, Clarke R, West CE, Katan MB, Verhoef P. Folic acid and reduction of plasma homocysteine concentrations in older adults: a dose-response study. Am J Clin Nutr. 2003;77:1318-1323.
28. Spence JD, Cordy P, Kortas C, Freeman D. Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: no difference between 1 and 5 mg daily. Am J Nephrol. 1999; 18:405-410.
29. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202.
30. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ. 1998;316:894-898.
31. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. J Am Med Assoc. 2004;291:1071-1080.
32. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Beider R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
33. The VITATOPS Trial Study Group. The VITATOPS (Vitamins to Prevent Stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis. 2004;13:120-126.
34. Olthof MR, van Vliet T, Boelsma E, Verhoef P. Low dose betake supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J Nutr. 2003;133:4135-4138.
35. Lauterburg BH, Nguyen T, Hartmann B, Junker E, Kupfer A, Cerny T. Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol. 1994;35: 132-136.